Progress in Pediatric Cardiology
Volume 27, Issue 1 , Pages 57-61 , December 2009

Medical and non-medical considerations for the outpatient management of children with pulmonary arterial hypertension

  • Michelle T. Ogawa

      Affiliations

    • Corresponding Author InformationCorresponding author. Pediatric Cardiology, Vera Moulton Wall Center for Pulmonary Vascular Disease, Lucile Packard Children's Hospital at Stanford, 750 Welch Road, Suite 305 Palo Alto, CA 94304, United States. Tel.: +1 650 725 6538; fax: +1 650 725 8343.
    • ,
  • Darci A. Albrecht
    • ,
  • Esther Y. Liu

References 

  1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343–349
  2. Sandoval J, Baurele O, Gomez A, et al. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol. 1995;25:466–474
  3. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99:1197–1208
  4. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for children 2001–2006. Heart. 2009;95:312–317
  5. Yung D, Widlitz AC, Rosenzweig EB, et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation. 2004;110:660–665
  6. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patient with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–804
  7. Flolan [package insert]. Research Triangle, NC: GlaxoSmithKline; 2008;
  8. Remodulin [package insert]. Research Triangle, NC: United Therapeutics Corp; 2008;
  9. Tapson VF, McLaughlin V, Gomberg-Maitland M, et al. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension. J Vasc Access. 2006;7:112–117
  10. McLaughlin V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477–1482
  11. Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2003;167:580–586
  12. Sitbon O, Humbert M, Nunes H, et al. Long-term epoprostenol infusion in primary pulmonary hypertension. J Am Coll Cardiol. 2002;40:780–788
  13. Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol. 2007;99:696–698
  14. Kallen AJ, Lederman E, Balaji A, et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol. 2008;29:342–349
  15. Oudiz RJ, Widlitz A, Beckmann XJ, et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest. 2004;126:90–94
  16. Center for Disease Control. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension—Seven sites, United States, 2003–2006. Morb Mortal Wkly Rep. 2007;56:170–172
  17. Doran A, Ivy D, Barst RJ, et al. Guidelines for the prevention of central venous catheter-related bloodstream infections with prostanoid therapy for pulmonary arterial hypertension. Adv Pulm Hypertens. 2008;7:245–248
  18. Akagi S, Matsubara H, Ogawa A, et al. Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension. Circulation. 2007;71:559–564
  19. Bouza E, Munoz P, Lopez-Rodriguez J, et al. A needleless closed system device (CLAVE) protects from intravascular catheter tip and hub colonization: a prospective randomized study. J Hosp Infect. 2003;54:279–287
  20. Dickinson MG, Scholvinck EH, Boonstra A, et al. Low complication rates with totally implantable access port use in epoprostenol treatment of pulmonary hypertension. J Heart Lung Transplant. 2009;28:273–279
  21. Ponec D, Irwin D, Haire WD, et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial—the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol. 2001;12:951–955
  22. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task on Expert Consensus Documents and the American Heart Association. Circulation [serial online]. April 2009;
  23. [23] Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med;327-76-81.
  24. Desai SA, Channick RN. Exercise in patients with pulmonary arterial hypertension. J Cardiopulm Rehabil Prev. 2008;28:12–16
  25. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006;114:1482–1489
  26. Petersen DF, Bishop VS, Erickson HH. Cardiovascular changes during and following 1-minute exposure to +GZ stress. Aviat Space Environ Med. 1975;46:775–779
  27. Federal Aviation Administration (FAA) (no author). FAA approved portable oxygen concentrators positive testing results. FAA website. 2009. Available at: http://www.faa.gov/safety/programs_initiatives/aircraft_aviation/cabin_safety/portable_oxygen/Accessed June 12, 2009.

PII: S1058-9813(09)00032-0

doi: 10.1016/j.ppedcard.2009.09.009

Progress in Pediatric Cardiology
Volume 27, Issue 1 , Pages 57-61 , December 2009

Article Tools

* Image Usage & Resolution